The RBD-VLP antigen was formulated with one of two adjuvants: aluminum hydroxide (alum) and a combination of alum with CpG1018 – a potent commercial adjuvant that is known to elicit T helper 1 ...

VLP vaccines benefit from the VLP’s ability to present antigens in a repetitive manner, which allows for the cross-linking of B cell receptors (BCRs).

(MENAFN- ForPressRelease) Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is pleased to announce the availability of its new line of Norovirus VLP ...

- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now focused on a bivalent strategy for COVID-19 ...

Premas Biotech’s COO Nupur Mehrotra said, “We have generated well characterized VLPs with earlier mutations - alpha, beta, gamma and delta variants into the triple antigen VLP framework within ...

- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen ...

Utilizing this -VLP technology and leveraging its potency, VLP Therapeutics successfully developed a new compound by inserting a target antigen into the specific area of VLPs (thus, "inserted" or ...

Icosavax launches with $51 million to advance IVX-121, a RSV vaccine candidate, built with two-component virus-like particle (VLP) technology.

The bivalent vaccine formulation involved in the trial includes antigens from both norovirus genogroups that commonly infect humans. LigoCyte’s bivalent vaccine is designed to provide protection ...